ES2125251T3 - Inhibidores de la proteasa del vih. - Google Patents

Inhibidores de la proteasa del vih.

Info

Publication number
ES2125251T3
ES2125251T3 ES92309639T ES92309639T ES2125251T3 ES 2125251 T3 ES2125251 T3 ES 2125251T3 ES 92309639 T ES92309639 T ES 92309639T ES 92309639 T ES92309639 T ES 92309639T ES 2125251 T3 ES2125251 T3 ES 2125251T3
Authority
ES
Spain
Prior art keywords
treatment
hiv protease
protease inhibitors
hiv
aids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92309639T
Other languages
English (en)
Inventor
Wayne J Thompson
Arun K Ghosh
Hee Yoon Lee
Joel R Huff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of ES2125251T3 publication Critical patent/ES2125251T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

SE DESCRIBEN ANALOGOS DE OLIGOPEPTIDOS. ESTOS COMPUESTOS SON UTILES EN LA INHIBICION DE LA PROTEASA DEL VIH, LA PREVENCION O TRATAMIENTO DE LA INFECCION PROVOCADA POR EL VIH Y EL TRATAMIENTO DEL SIDA, BIEN COMO COMPUESTOS, SALES FARMACEUTICAMENTE ACEPTABLES, INGREDIENTES DE COMPOSICIONES FARMACEUTICAS, TANTO SI SE ENCUENTRAN COMBINADOS O NO CON OTROS AGENTES ANTIVIRALES, INMUNOMODULADORES, ANTIBIOTICOS O VACUNAS. TAMBIEN SE DESCRIBEN METODOS PARA EL TRATAMIENTO DEL SIDA Y METODO PARA PREVENIR O TRATAR LA INFECCION PROVOCADA POR EL VIH.
ES92309639T 1991-10-23 1992-10-21 Inhibidores de la proteasa del vih. Expired - Lifetime ES2125251T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78147091A 1991-10-23 1991-10-23
US92999192A 1992-08-21 1992-08-21

Publications (1)

Publication Number Publication Date
ES2125251T3 true ES2125251T3 (es) 1999-03-01

Family

ID=27119862

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92309639T Expired - Lifetime ES2125251T3 (es) 1991-10-23 1992-10-21 Inhibidores de la proteasa del vih.

Country Status (11)

Country Link
US (1) US5502060A (es)
EP (1) EP0539192B1 (es)
JP (1) JPH0678314B2 (es)
AT (1) ATE175412T1 (es)
AU (1) AU649170B2 (es)
CA (1) CA2081134A1 (es)
DE (1) DE69228106T2 (es)
ES (1) ES2125251T3 (es)
IL (1) IL103459A0 (es)
NZ (1) NZ244773A (es)
WO (1) WO1993008184A1 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313094B1 (en) 1990-12-11 2001-11-06 Japan Energy Corporation β-amino-α-hydroxycarboxylic acid derivatives and HIV protease inhibitors
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
JPH07504654A (ja) 1992-03-11 1995-05-25 ナルヘックス　リミテッド オキソ及びヒドロキシ置換炭化水素のアミン誘導体
US5888992A (en) 1992-03-11 1999-03-30 Narhex Limited Polar substituted hydrocarbons
US6071895A (en) 1992-03-11 2000-06-06 Narhex Limited Polar-substituted hydrocarbons
DE69333270T2 (de) 1992-03-11 2004-08-05 Narhex Ltd. Aminderivate von oxo- und hydroxy- substituierten kohlenwasserstoffen
JP3657002B2 (ja) 1992-08-25 2005-06-08 ジー．ディー．サール アンド カンパニー レトロウイルスプロテアーゼ阻害剤として有用なα−およびβ−アミノ酸ヒドロキシエチルアミノスルホンアミド
US7141609B2 (en) 1992-08-25 2006-11-28 G.D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5846993A (en) * 1992-12-22 1998-12-08 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
AU6828894A (en) * 1993-05-14 1994-12-12 Merck & Co., Inc. Hiv protease inhibitors
HUT74681A (en) * 1993-12-15 1997-01-28 Merck & Co Inc N-(2-hydroxy-1-indenyl)-2-phenylmethyl-4-hydroxy-5-(2-carboxamido-piperazinyl)-pentaneamide derivatives of hiv protease inhibitor activity and phrmaceutical compositions contining them
US5733882A (en) * 1994-01-17 1998-03-31 Smithkline Beecham Corporation Retroviral protease inhibitors
US5480887A (en) * 1994-02-02 1996-01-02 Eli Lilly And Company Protease inhibitors
CA2182090A1 (en) * 1994-02-02 1995-08-10 William Joseph Hornback Hiv protease inhibitors and intermediates
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5932550A (en) * 1995-06-30 1999-08-03 Japan Energy Corporation Dipeptide compound or pharmaceutically acceptable salt thereof and medical use thereof
US6222043B1 (en) 1995-06-30 2001-04-24 Japan Energy Corporation Methods of preparing novel dipeptide compounds or pharmaceutically acceptable salts thereof
DE19531685A1 (de) * 1995-08-29 1997-03-06 Bayer Ag Neue heterocyclisch substituierte Pseudopeptide
US5962725A (en) 1996-09-05 1999-10-05 Agouron Pharmaceuticals, Inc. Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
US5705647A (en) * 1996-09-05 1998-01-06 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US5925759A (en) 1996-09-05 1999-07-20 Agouron Pharmaceuticals, Inc. Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
CA2249747A1 (en) 1996-12-27 1998-07-09 Tsutomu Mimoto Novel tripeptide compounds and anti-aids drugs
US6001851A (en) * 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US6084107A (en) * 1997-09-05 2000-07-04 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
EP1039886A4 (en) * 1997-12-08 2001-05-16 Scripps Research Inst HIV / LIV PROTEASES INHIBITORS WITH SMALL P3 REST
US6803466B1 (en) * 1997-12-08 2004-10-12 The Scripps Research Institute HIV/FIV protease inhibitors having a small P3 residue
JP4776775B2 (ja) * 1998-06-23 2011-09-21 アメリカ合衆国 Ｈｉｖ感染哺乳動物を治療するための医薬組成物
WO1999067254A2 (en) * 1998-06-23 1999-12-29 The United States Of America Represented By The Secretary, Department Of Health And Human Services Multi-drug resistant retroviral protease inhibitors and use thereof
AU2492500A (en) * 1999-01-06 2000-07-24 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Aspartic protease inhibitors, compositions, and associated therapeutic methods
CA2374346C (en) * 1999-06-28 2010-06-22 Jordan J. N. Tang Inhibitors of memapsin 2 and use thereof
JP2003531865A (ja) * 2000-04-28 2003-10-28 アメリカ合衆国 Ｄｎａおよびワクシニアウイルスベクターワクチンの組み合わせを用いた免疫原性の改善
US20040009890A1 (en) * 2002-01-07 2004-01-15 Erickson John W. Broad spectrum inhibitors
US7157489B2 (en) * 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
US20060094006A1 (en) * 2002-05-01 2006-05-04 Genoveffa Franchini Immunotherapy regimens in hiv-infected patients
WO2004060895A1 (ja) 2002-12-27 2004-07-22 Sumitomo Chemical Company, Limited ヘキサヒドロフロフラノール誘導体の製造方法、その中間体及びその製造方法
CA2559328A1 (en) * 2004-03-11 2005-09-22 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
JP2005314374A (ja) * 2004-03-31 2005-11-10 Daiso Co Ltd ３−ヒドロキシチオランの新規製法
MXPA06012909A (es) 2004-05-07 2007-09-06 Sequoia Pharmaceuticals Inc Inhibidores de proteasa retroviral repelente de resistencia.
EP1922083A2 (en) * 2005-08-10 2008-05-21 Oklahoma Medical Research Foundation Truncated memapsin 2 for use for treating alzheimer's disease
WO2007028985A2 (en) * 2005-09-07 2007-03-15 The Secretary Of State For Defence Adjuvanted vaccine
GB0519871D0 (en) * 2005-09-30 2005-11-09 Secr Defence Immunogenic agents
EP2040744B1 (en) 2006-07-25 2016-03-09 The Secretary of State for Defence Live vaccine strains of francisella
GB0900455D0 (en) 2009-01-13 2009-02-11 Secr Defence Vaccine
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
US20130052221A1 (en) 2010-02-26 2013-02-28 The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services Dna-protein vaccination protocols
KR101680302B1 (ko) * 2010-07-13 2016-11-29 김찬숙 세포의 다핵분열을 유도할 수 있는 조성물
PT2643326T (pt) 2010-11-23 2016-12-23 Mylan Laboratories Ltd Processo para a preparação de (3r,3as,6ar)-hexa-hidrofuro[2,3-b]furan-3-ol
ES2657227T3 (es) 2012-08-09 2018-03-02 Sumitomo Chemical Company, Limited Método para producir un derivado de hexahidrofurofuranol
EP4276106A3 (en) 2015-05-13 2024-01-24 The United States of America as represented by the Secretary of the Department of Health and Human Services Methods and compositions for inducing an immune response using conserved element constructs
EP4551247A1 (en) 2022-07-07 2025-05-14 The United States of America, as represented by the Secretary, Department of Health and Human Services Immunogens and methods for inducing an immune response

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
CA2012306A1 (en) * 1989-03-28 1990-09-28 Werner Neidhart Amino acid derivatives
GB8927915D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
CA2032259A1 (en) * 1989-12-18 1991-06-19 Wayne J. Thompson Hiv protease inhibitors useful for the treatment of aids

Also Published As

Publication number Publication date
DE69228106T2 (de) 1999-07-15
JPH05239031A (ja) 1993-09-17
EP0539192A1 (en) 1993-04-28
AU2725392A (en) 1993-04-29
AU649170B2 (en) 1994-05-12
ATE175412T1 (de) 1999-01-15
WO1993008184A1 (en) 1993-04-29
IL103459A0 (en) 1993-03-15
JPH0678314B2 (ja) 1994-10-05
CA2081134A1 (en) 1993-04-24
DE69228106D1 (de) 1999-02-18
US5502060A (en) 1996-03-26
EP0539192B1 (en) 1999-01-07
NZ244773A (en) 1994-10-26

Similar Documents

Publication Publication Date Title
ES2177868T3 (es) Hidroxietilaminosulfonamidas de alfa- y beta-aminoacidos utiles como inhibidores de proteasas retroviricas.
ES2151897T3 (es) Benzoxazinonas como inhibidores de la transcriptasa inversa de vih.
MX9403380A (es) Inhibidores de proteasa de vih utiles para el tratamiento de sida.
MX9204720A (es) Derivados de quinazolina como inhibidores de transcriptasa inversa de vih.
ES2112880T3 (es) Inhibidores de la proteasa de vih utiles para el tratamiento del sida.
ATE175412T1 (de) Hiv-protease-inhibitoren
ES2132201T3 (es) Inhibidores de la hiv proteasa utiles en el tratamiento del sida.
ES2150933T3 (es) Inhibidores de la proteasa vih utiles para el tratamiento del sida.
ES2174921T3 (es) Inhibidores de la proteasa del vih.
ATE377011T1 (de) Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1- piperazinpentanamide als hiv-proteasehemmer
ES2186787T3 (es) Utilizacion de ritonavir (abt-538) para mejorar la farmacocinetica de medicamentos metabolizados por el citocromo p450 en un metodo de tratamiento del sida.
ES2188604T3 (es) Inhibidores de proteasa del vih en combinaciones farmaceuticas para eltratamiento del sida.
ES2101252T3 (es) Inhibidores de la proteasa del hiv utiles para el tratamiento del sida.
ATE147981T1 (de) Verabreichung von lamotrigin zur behandlung von neuro-aids
YU172991A (sh) Sinergizam inhibitora hiv reverzne transkriptaze
ES2183817T3 (es) Inibidores de proteasas de parasatiso metazoarios.
ES2176263T3 (es) 5,6-dihidropironas derivadas como inhibidores de proteasa y agentes antivirus.
CO4130200A1 (es) Inhibidores de proteasa del hiv utiles en el tratamiento del sida
MX9308010A (es) Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
MX9302681A (es) Nuevas quinazolinas como inhibidores de transcriptasa inversa hiv.
MX9705916A (es) Terapia de combinacion para infeccion por vih usando el inhibidor de proteasa de vih indinavir y el inhibidor de transcriptasa inversa 3tc, opcionalmente junto con azt, ddi, o ddc.
MX9700036A (es) Combinacion de compuestos, uso en la preparacion de composiciones para tratar infeccion por el vir s de inmunodeficiencia humana, y composiciones obtenidas.
ES2190456T3 (es) Combinacion de inhibidores de la proteasa del vih.
UA41338C2 (uk) Спосіб інгібування ретровірусної інфекції, яка викликана вірусом імунодефіциту людини (віл), спосіб інгібування вірусу імунодефіциту людини (віл)
ECSP003786A (es) Gama-hidroxil-2 (fluoroalquiloaminocarbonil)-1-piperacinapentanamidas y usos de ellas

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 539192

Country of ref document: ES